Clinical trial
A Randomized, Double-blind, Dose Ranging Study to Determine the Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Patients With ALS
NCT00409721 is registered in ClinicalTrials.gov with University of Alberta as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Dose Ranging Study to Determine the Effect of Memantine on Functional Outcomes and Motor Neuron Degeneration in Patients With ALS
- Lead sponsor
- University of Alberta
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2007
- Completion date
- December 31, 2010
- Enrollment
- 42 (estimated)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.